Review: In relapsing–remitting multiple sclerosis, disease-modifying agents reduce annual relapse rates

Abstract

ACP Journal Club18 March 2014Review: In relapsing–remitting multiple sclerosis, disease-modifying agents reduce annual relapse ratesBrian G. Weinshenker, MD, FRCP(C)Brian G. Weinshenker, MD, FRCP(C)Mayo Clinic, Rochester, Minnesota, USA (B.G.W.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-160-6-201403180-02005 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationCADTH Therapeutic Reviews. Management of relapsing–remitting multiple sclerosis [Internet]. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health;Oct 2013. https://pubmed.ncbi.nlm.nih.gov/24279002Clinical Impact RatingsGIM/FP/GP: Neurology: References1 Complete response letter for Lemtrada: Genzyme receives complete response letter from FDA on Lemtrada (alemtuzumab) application. www.drugs.com/nda/lemtrada_131230.html (accessed 8 Jan 2014). Google Scholar2 Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest. 2009;119:2052-61. [PMID: 19546505] Google Scholar Author, Article, and Disclosure InformationAffiliations: Mayo Clinic, Rochester, Minnesota, USA (B.G.W.)This article was published at Annals.org on 4 March 2014. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byMarkers of oxidative stress in plasma and saliva in patients with multiple sclerosis 18 March 2014Volume 160, Issue 6Page: JC5KeywordsDrugsInterferonsInternetLesionsMultiple sclerosisNetwork analysisNeurologyOral administrationSafety ePublished: 18 March 2014 Issue Published: 18 March 2014 Copyright & PermissionsCopyright © 2014 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...